Acquisition of 6730 equity shares of Havix Group Inc. D/A Aavis Pharmaceuticals, subsidiary of the Company

Senores Pharmaceuticals Limited has informed the Exchange regarding acquisition of 6730 equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals, subsidiary of the Company. and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) - Acquisition of 6730 Equity. D/B/A Aavis Pharmaceuticals (“Havix” or “the Target Company”) for acquisition of 6730 (Six Thousand Seven.

An acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.

• Consideration and how it is funded
• Revenue and profit of the target
• Expected completion date
• Based on the current business outlook and execution visibility, we expect the revenue growth of approximately (management committed by FY27)
• FY’27. So, next year, FY’27, we feel that margin when we get to about 18%, 20% to 22% kind of a number should (management committed by FY27)